ToxSci Advance Access originally published online on December 28, 2005
Toxicological Sciences 2006 90(2):362-368; doi:10.1093/toxsci/kfj087
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endocrine Disrupting Chemical Atrazine Causes Degranulation through Gq/11 Protein-Coupled Neurosteroid Receptor in Mast Cells
Division of Molecular Pharmacology and Neuroscience, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
1 To whom correspondence should be addressed at Division of Molecular Pharmacology and Neuroscience, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan. Fax: +81-95-819-2420. E-mail: ueda{at}net.nagasaki-u.ac.jp.
Received October 15, 2005; accepted December 20, 2005
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
We studied the effects of representative endocrine-disrupting chemicals on ß-hexosaminidase release from mast cells and their putative neurosteroid receptor involvement. Some endocrine-disrupting chemicals, such as amitrol, benzophenon, bisphenol A, pentachlorophenol, and tetrabromophenol A did not cause hexosaminidase release from RBL-2H3 cells, but they blocked the release by dehydroepiandrosterone sulfate, a representative neurosteroid agonist. On the contrary, atrazine, which is a widely used herbicide, caused a rapid and concentration-dependent degranulation in the range between 10 nM and 1 µM in RBL-2H3 and peritoneal mast cells. Atrazine-induced degranulation was also evaluated by Alexa 488-annexin V binding to the phosphatidylserine, which is externalized during degranulation, and these actions were blocked by BSA-conjugated (membrane-impermeable) progesterone (PROG-BSA). The atrazine-induced ß-hexosaminidase release was characterized by various inhibitors including antisense-oligodeoxynucleotide for G
q/11, pertussis toxin, phospholipase C inhibitor U-73122, inositol 1,4,5-triphosphate receptor inhibitor xestospongin C and Ca2+ channel blocker lanthanum chloride. These analyses revealed that the degranulation is mediated by putative metabotropic neurosteroid receptor, Gq/11, phospholipase C and Ca2+ mobilization from intracellular stores. Having documented progesterone receptor-modulation of atrazine-induced mast cell degranulation in vitro, this response was evaluated in mice. Atrazine caused pain responses when injected in the foot pads of mice, and they were antagonized by local administration of PROG-BSA or diphenhydramine. Atrazine also caused PROG-BSA-reversible plasma extravasation. All these findings strongly suggest that herbicide atrazine exerts inflammatory activity through activation of putative Gq/11-coupled neurosteroid receptor and phospholipase C. Key Words: degranulation; endocrine-disrupting chemical; extravasation; mast cell; neurosteroid.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
Endocrine disrupting chemicals (EDCs) are known to mimic the actions of sex steroid hormones and to cause serious dysfunction of reproductive organs through disruption of endocrine homeostasis (McLachlan, 2001
). These actions are largely attributed to genomic actions through nuclear steroid receptors. However, some other biological actions of endocrine disrupting chemicals include non-genomic and acute responses (Chen, 2001). These are thought to be mediated through the central nervous system, therefore, several studies have been carried out on the psychoactive actions of neurosteroids (Dohi et al., 2004).
Neurosteroids are synthesized de novo in the nervous system and have a wide variety of functions (Baulieu, 1989; Rupprecht and Holsboer, 1999). They exert their actions not only through classical nuclear steroid hormone receptors, but also through plasma membrane receptors (Baulieu, 1989; Nadal et al., 2001). Although many studies have demonstrated that the non-genomic actions of neurosteroids are due to allosteric actions on ligand-gated channels such as GABAA (Majewska et al., 1986) and NMDA receptors (Wu et al., 1991), we have previously shown in reconstitution experiments that some neurosteroids share pharmacological activity with a putative Gi-coupled 
receptor in the brain (Ueda et al., 2001b). Recently, we have demonstrated that pregnenolone sulfate and dehydroepiandrosterone sulfate (DHEAS), two representative neurosteroids, induce nociceptive flexor responses through two novel types of neurosteroid receptors, termed neuronal NS1/-type and non-neuronal NS2-type (Ueda et al., 2001a). In that study we proposed that the latter NS2-type neurosteroid receptor exists on mast cells and mediates histamine release, which, in turn, stimulates nociceptor endings. Other studies have demonstrated that neurosteroids cause extravasation as well as hyperalgesia, which were abolished by diphenhydramine, a representative H1 receptor antagonist (Uchida et al., 2003). It is of great significance that 1,1-dichloro-2,2-bis (p-chlorophenyl) ethylene (p,p'-DDE), which is a metabolite of dichlorodiphenyltrichloroethane (DDT) and listed as an EDC, blocks these actions by acting as a pure antagonist. More recently, we found that neurosteroid-induced extravasation are attributed to degranulation of mast cells (Uchida et al., 2003). Although representative EDCs, nonylphenol and 4-octylphenol showed no extravasation by themselves, they have antagonist effects. Therefore, as far as acute inflammatory effects are concerned, these EDCs without extravasation effects may cause no serious ecological problems.
Atrazine, an herbicide, is still commonly used in the U.S. (US EPA, 2003), despite the report that atrazine has disruptive effects on the reproductive system in wild animals and humans (Hayes et al., 2002). It should be noted that up to 92% of male leopard frogs show gonadal abnormalities, such as retarded development and hermaphroiditism, on exposure to water-borne atrazine contamination. In the course of extensive study to evaluate the effects of more EDCs on the mast cell degranulation, we found that atrazine causes potent degranulation and related inflammatory actions, which may further warn the ecological problems. Here we focused our concerns on the mechanisms underlying these acute and non-genomic actions.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
Chemicals.
The following chemicals were obtained from Sigma (St. Louis, MO): Compound 48/80, dehydroepiandrosterone sulfate (DHEAS), progesterone (PROG), PROG 3-(O-carboxymethyl) oxime:BSA (PROG-BSA) (steroid:BSA, 38:1), PROG-BSA-fluorescein isothiocyanate conjugate (PROG-BSA-FITC), lanthanum chloride, N-acetyl-ß-D-glucosaminide, quercetin and RU486. ICI-182,780, Evans blue were purchased from Wako (Osaka, Japan). Atrazine was purchased from Kanto Kagaku (Tokyo, Japan). Amitrol, bisphenol, benzophenone, pentachlorophenol, and tributylphenol A were gifts from Dr. Funae (Osaka City University, Japan). Xestospongin C, which is also called araguspongine E (Kobayashi et al., 1989
) was a gift from Dr. Kobayashi (Osaka Univ., Japan). Alexa 488 annexin-V-fluorescein reagent was obtained from Funakoshi (Tokyo, Japan). The antisense oligodeoxynucleotide (AS-ODN, 5'-ATGGACTCCAGAGT-3') for rat Gq/11 and its mismatch oligodeoxynucleotide (MS-ODN, 5'-AGTGACCTCAGGAT-3') were synthesized as described previously (Ueda and Inoue, 2000). All oligodeoxynucleotides (ODNs) were purchased from QIAGEN (Tokyo, Japan). Anti-Gq/11 was obtained from NEN Life Science Products (Boston, MA).
Cell culture.
RBL-2H3 cells were maintained in minimum essential medium (MEM) supplemented with 10% fetal bovine serum, L-glutamine and penicillin/streptomycin. In most experiments, unless otherwise stated, RBL-2H3 cells were treated with 30 µM quercetin for 48 h. Quercetin, prepared as a 60 mM stock solution in propylene glycol was added to up-regulate Gi, since this treatment makes it easier to detect the ß-hexosaminidase release by Gi-mediated mechanisms, as seen with Compound 48/80, known to degranulate mast cells (Senyshyn et al., 1998). Although the deletion of quercetin from the culture did not change the DHEAS-induced ß-hexosaminidase release (Supplementary Data 1), the present study was carried out in the presence of quercetin in order to compare the signal transduction with the previous report (Mizota et al., 2005).
For each experiment, the cells were incubated overnight in complete growth medium and then with pertussis toxin (PTX; 100 ng ml–1) for 12 h, or U-73122 (100 nM), U-73343 (100 nM), xestospongin C (1 µM), lanthanum chloride (50 µM), wortmannin (1 µM), RU-486 (1 µM), ICI-182,780 (1 µM) for 10 min before addition of the test drugs. Test drugs were dissolved in 100% methanol to 0.02 M, and diluted to make 1 µM in HEPES-Tyrode buffer (140 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 5.6 mM glucose, 12 mM NaHCO3, 0.37 mM NaH2PO4 · 2H2O, 25 mM HEPES, 0.49 mM MgCl2, 0.1% BSA, pH 7.4 adjusted with NaOH). The antisense-oligodeoxynucleotide (AS-ODN) or its mismatch-oligodeoxynucleotide (MS-ODN) for Gq/11 (20 µM) was added to the culture of RBL-2H3 cells every 8 h for 48 h, followed by wash with serum-free MEM and with HEPES-Tyrode BSA assay buffer. The treated cells (5 x 104 cells/well) were suspended in 200 µl of HEPES-Tyrode BSA buffer and used for the ß-hexosaminidase release assay. Western blot analysis was performed as reported previously (Ueda and Inoue, 2000), using the antiserum against Gq/11 (1:1000 dilution).
Peritoneal mast cell isolation.
The experiment was performed as previously described (Fish et al., 2005; Mori et al., 2000). Male ddY mice (5 weeks) were euthanized by CO2-asphyxia. Normal Hepes-buffered Ringer solution (HR; 118mM NaCl, 4.7 mM KCl, 2.5mM CaCl2, 1.13mM MgCl2, 1.0 mM NaH2PO4, 10 mM D-glucose, 10 mM HEPES, MEM, 0.1% bovine serum albumin; pH 7.4, adjusted with NaOH; approximately 10 ml) was injected intraperitoneally and the abdomen was gently massaged for approximately 5 min. The HR-buffer from the peritoneal cavity was centrifuged at 2000 rpm for 5 min, and the eluted peritoneal cells containing the mast cells were harvested. After the addition of several ml of fresh HR-buffer, the cell suspensions were plated, grown to confluence, in 24-well plates coated with lysine-collagen.
Measurement of ß-hexosaminidase release.
The experiment was performed as previously described (Hong-Geller and Cerione, 2000; Zussman and Sagi-Eisenberg, 2000). RBL-2H3 or peritoneal mast cells cells were seeded in 24-well plates, grown to confluence, incubated in growth medium containing 30 µM quercetin and washed twice with HEPES-Tyrode BSA buffer, and suspended in 200 µl of HEPES-Tyrode BSA buffer at 37°C. The cells were then stimulated with various drugs for 10 min or the indicated periods at 37°C and harvested by spin-down. Hundred µl aliquots of the supernatants were collected and incubated with 50 µl 10 mM N-acetyl-ß-D-glucosaminide in 0.05 M citrate buffer (pH 4.5) for 1 h at 37°C. To determine the total amount of ß-hexosaminidase, the cells were lysed with 0.1% Triton X-100. The absorbance at 405 nm was read in a microplate reader (Bio-Rad 550; Nippon Bio-Rad Laboratories, Osaka, Japan).
Alexa 488-Annexin-V staining assay.
The experiment was performed as previously described (Demo et al., 1999; Windmiller and Backer, 2003). To study mast cell degranulation in single cells, RBL-2H3 cells (5.0 x 104 cells well–1) grown on lysine–collagen coated coverslips were cultured for 24 h, washed in HEPES-Tyrode BSA buffer and stimulated by test drug for 10 min at 37°C in the presence of 1:10 dilution of Alexa 488-labeled annexin-V, which binds to phosphatidylserine in the outer leaflet of the plasma membrane of degranulated mast cells. The cells were washed with phosphate-buffered saline (PBS), fixed in 4% (w/v) paraformaldehyde for 30 min at room temperature, washed three times with PBS and then mounted. The Alexa 488-annexin V positive cells were counted using a fluorescence microscope (Axiovert 135, Zeiss, Germany). Images were acquired with NIH image 1.63 analysis software. The Alexa 488-annexin V-based assay accurately reflects ligand-stimulated degranulation of RBL-2H3 cells.
PROG-BSA-FITC binding assay.
The experiment was performed as previously described (Benten et al., 1999; Nadal et al., 2000). RBL-2H3 cells (1 x 105 cells well–1) cultured on polylysine-coated coverslips for 24 h were fixed with 2% (w/v) paraformaldehyde for 15 min, and washed three times with PBS. The cells were incubated with 1 µM PROG-BSA-FITC at room temperature for 2 h and washed. Endocrine disrupting chemicals were added to the cell for 30 min before the start of the PROG-BSA-FITC binding. FITC-labeled cells were analyzed using a confocal laser scanning microscope (Axiovert 135, Zeiss, Germany), after excitation of FITC fluorescence by a 488 nm argon laser.
Animals and behavioral studies.
The pain-producing substance-induced biting and licking (pain-like behavior) test was performed as described previously (Uchida et al., 2003). Male ddY mice weighing 20–22 g were used in all experiments. The experimental procedures were approved by the Nagasaki University Animal Care Committee and complied with the recommendations of the International Association for the Study of Pain (Zimmermann, 1983). Test drugs were administered intraplantarly into the hind paw. Mice were adapted to individual transparent plastic cages, which served as observation chambers, for 1 h prior to intraplantar (i.pl.) injection. Immediately after injection, each mouse was re-placed in the cage over a mirror and behavioral testing was initiated. The total amount of time showing pain responses, such as biting and licking, was measured for 10 min after i.pl. injection. All drugs were first dissolved in 100% methanol to make 20 mM and diluted to make 10 fmol in 20 µl physiological saline. As the dilution is so high, no significant in vivo effect of methanol was expected. All drugs were dissolved in physiological saline, and administered by i.pl. injection in a volume of 20 µl. All mice were only used once.
Evans blue extravasation test.
Evans blue extravasation assay was performed as described previously (Uchida et al., 2003). Mice were anaesthetized with pentobarbital (50 mg kg–1, ip) and injected with Evans blue (50 mg kg–1, iv) into the tail vein. Antagonist PROG-BSA, diphenhydramine (DPH) and atrazine were administered by i.pl. injection 10 and 15 min later, respectively. Twenty-five min after atrazine injection, the plantar skin of the paw was removed, dried of excess liquid, weighed (0.03–0.05 g wet weight) and incubated in formamide for 24 h at 55°C. Extravasated Evans blue was measured by spectrophotometry at 620 nm. Results are expressed as the ratio of arbitrary fluorescence units for Evans blue of drug-treated paw to that of vehicle-treated paw.
Statistical analysis.
Results of all experiments were expressed as the mean ± SE and analyzed by one-way ANOVA with Scheffe's test. Significance was set at p < 0.05.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
Atrazine-Induced Rapid Degranulation in RBL-2H3 Cells
Degranulation of mast cells was determined by measuring the release of granule-associated ß-hexosaminidase from RBL-2H3 cells, as previously reported (Mizota et al., 2005
), in which dehydroepiandrosterone sulfate (DHEAS)-induced ß-hexosaminidase release was inhibited by co-administration of 10 µM nonylphenol, 4-octylphenol, or PROG-BSA (10 µM). As shown in Figure 1A, DHEAS and atrazine at 1 µM showed significant degranulation, while other EDCs, such as amitrol, benzophenon, bisphenol A, pentachlorophenol, and tetrabromophenol A did not. However, these EDCs showed potent antagonist activity against DHEAS- or atrazine-induced degranulation (Figs. 1B and 1C). As shown in Figures 1D and 1E, atrazine-induced ß-hexosaminidase release was dose-dependent between 10 nM and 1 µM, and significant change was observed as early as 10 min after the addition. As seen in the case with DHEAS, atrazine-induced ß-hexosaminidase release was blocked by PROG-BSA (10 µM), a membrane impermeable neurosteroid receptor antagonist (Fig. 1F). However no EDCs caused any cytotoxic effects on the cells, as evaluated by the Trypan blue exclusion assay (data not shown). Similar atrazine-induced degranulation and its PROG-BSA reversibility were observed in peritoneal mast cells (Figs. 1G and 1H). DHEAS and atrazine at 1 µM caused significant release by 4.6 and 3.8% of total contents, respectively from these cells.
|
Single-Cell Assay for Mast Cell Degranulation
It is reported that degranulation is accompanied by externalization of outer surface membrane phosphatidylserine, which is labeled by Alexa 488-labeled annexin-V (Demo et al., 1999
; Windmiller and Backer, 2003). The addition of Alexa 488-annexin V alone to RBL-2H3 cells showed no significant fluorescence, whereas further addition of atrazine (10 µM) caused some dotted fluorescent signals in most of cells (Fig. 2A). As shown in Figure 2B, similar membrane externalization was also observed with DHEAS (10 µM), but not PROG-BSA, while PROG-BSA abolished both atrazine- and DHEAS-mediated binding (Fig. 2B).
|
|
Atrazine-Reversible PROG-BSA-FITC Binding |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
This experiment was determined as previously reported (Mizota et al., 2005
). RBL-2H3 cells cultured on polylysine-coated coverslips were fixed with paraformaldehyde, washed three times with PBS and used for binding experiments with 1 µM PROG-BSA-FITC. FITC-labeled cells were analyzed using a confocal laser scanning microscope. Fluorescence was only observed at the cell surface, and the addition of high concentration atrazine (10 µM) completely abolished the binding, as shown in Figure 3. Similar inhibition was observed with 10 µM pentachlorophenol, which showed the strongest inhibition of DHEAS-induced degranulation (Fig. 3). Amitrol, benzophenon, also blocked the binding (data not shown).
|
Signal Transduction of Atrazine-Induced ß-Hexosaminidase Release
Atrazine-induced ß-hexosaminidase release was characterized by the use of various inhibitors. Pretreatment with pertussis toxin (100 ng ml–1), which inhibits compound 48/80 (10 µg ml–1)-induced degranulation (Mizota et al., 2005
), had no effect (Fig. 4A). In contrast, pretreatment with AS-ODN for Gq/11, but not its MS-ODN, markedly reduced atrazine-induced ß-hexosaminidase release (Fig. 4B). As shown in the inset of Fig. 4B, AS-ODN significantly reduced the amount of Gq/11 protein in RBL-2H3 cells. Atrazine-induced degranulation was significantly abolished by phospholipase C (PLC) inhibitor U-73122 at 100 nM, but not by its inactive derivative U-73343 at 100 nM (Fig. 4A). Although xestospongin C at 1 µM, an allosteric inositol trisphosphate receptor antagonist (Gafni et al., 1997) also blocked the release, lanthanum chloride at 50 µM, which inhibits Ca2+ influx in cells (Aussel et al., 1996), did not. These results suggest that Ca2+ mobilization from intracellular stores, but not Ca2+ influx, is involved in this mechanism. On the other hand, neither nuclear PROG receptor antagonist RU486 (1 µM) nor estradiol receptor antagonist ICI-182,780 (1 µM) (Baulieu, 1989; Howell et al., 2000) caused any significant reduction in atrazine-induced degranulation. Therefore, known genomic effects are unlikely involved in this degranulation.
|
Atrazine-Induced Rapid Inflammatory Effects
Previously, we have reported that intraplantarly administered neurosteroids cause pain-like responses, such as biting and licking behaviors, in a diphenhydramine-reversible manner (Mizota et al., 2005
). In these studies, DHEAS (1–30 fmol, i.pl.) induced pain behaviors for 5–25 s in 10 min observation. As shown in Figure 5A, atrazine caused similar acute pain responses at a dose of 3 fmol per 20 µl, while other EDCs (amitrol, benzophenon, bisphenol A, pentachlorophenol, and tetrabromophenol A) alone caused no significant responses, but showed significant blockade of DHEAS- or atrazine-effects (Figs. 5B and 5C). Atrazine-induced pain responses occurred immediately and ceased within 5 min after the administration (Fig. 5D). The responses were dose-dependent between 1 and 10 fmol (i.pl.), blocked by PROG-BSA or DPH (Figs. 5E–5G).
|
Atrazine (10 fmol) increased the vascular permeability in terms of blue color at the injection site of the paw skin, when observed 10 min after systemic injection of Evans blue (Fig. 6A). This atrazine-induced vascular extravasation was abolished by PROG-BSA or DPH, which have no effects themselves in Evans blue extravasation.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
Our previous study demonstrated that some neurosteroids, such as pregnenolone sulfate and DHEAS cause degranulation in RBL-2H3 cells through putative Gq/11-coupled neurosteroid receptors, while PROG or its BSA-conjugate (PROG-BSA) block these actions (Mizota et al., 2005
). It should be noted that nonylphenol and bisphenol A have antagonist effects. The fact that EDCs have antagonist effects on cell surface neurosteroid receptors is also supported by Uchida et al. (2003), who showed that p,p'-DDE, a metabolite of DDT, antagonizes neurosteroid-induced hyperalgesia and extravasation. Similarly in the present study, we observed that some other EDCs such as amitrol, pentachlorophenol, benzophenon, bisphenol A, or tetrabromophenol A did not cause degranulation in terms of ß-hexosaminidase release from RBL-2H3 cells, but abolished the DHEAS-induced actions.
However, we found an exception, in which atrazine, a herbicide EDC caused degranulation and related inflammatory actions. Atrazine-induced ß-hexosaminidase release was blocked by membrane-impermeable BSA-conjugate PROG-BSA (Fig. 1F). Thus, it is evident that atrazine effects are mediated through putative membrane receptors. The atrazine-induced degranulation is unlikely due to cell damage, since it is also observed in a different assay using Alexa 488-annexin V binding to label phosphatidylserine externalized in the plasma membrane during degranulation (Demo et al., 1999; Smith et al., 2001). This atrazine-induced degranulation seems to be mediated through specific membrane receptors, since it was also reversible by PROG-BSA, but not by nuclear PROG or E2 receptor antagonists. Indeed, pharmacological characterization using specific inhibitors revealed that the signal transduction involved in this degranulation is mediated through Gq/11, PLC and mobilization of intracellular Ca2+, and all these characteristics are identical to those with neurosteroids. As previously reported (Mizota et al., 2005), neurosteroid-induced degranulation level was only 1–2% of the total content, which is comparable with atrazine-induced one, but much less than that through IgE receptors (10–15%). As a little more release by 1 µM DHEAS (4.6%) or atrazine (3.8%) was observed in peritoneal mast cells, however, such weak potencies in RBL-2H3 cells may be attributed to the low density of neurosteroid receptors.
Atrazine-induced degranulation was also supported by the in vivo studies (Figs. 5 and 6). Atrazine-induced pain responses were observed within as early as 5 min after the administration. As these effects were abolished by PROG-BSA and DPH, which is a histamine receptor antagonist, it is evident that they are caused by the neurosteroid receptor-mediated histamine release from mast cells. This view was supported by the atrazine-induced plasma extravasation assay using Evans blue. Throughout the present study, it is evident that atrazine also drives neurosteroid receptor-mediated mechanisms and causes some inflammatory effects, pathophysiological roles, in vivo. It is an important issue to be discussed that in vivo DHEAS or atrazine doses (10 fmol/20 µl, equivalent to 0.5 nM) required for induction of inflammatory actions are less than the in vitro concentrations (more than 10 nM) required for the degranulation. Although there is no clear answer, it might be possible that the mast cells existing in foot pad space may be more sensitive than those in RBL-2H3 or peritoneal mast cells. Alternatively, the histamine release required for induction of pain responses may be enough even if the mast cell degranulation is only partial. As reported in our previous study, such behavioral changes are related to the local amplification mechanism (Inoue et al., 1998). Taken this hypothesis, the initial weak histamine release would be enough to generate forthcoming bigger pain fiber stimulations.
In conclusion, we demonstrate that the herbicide atrazine induces some inflammatory effects, including nociception and plasma extravasation, and the underlying mechanisms are mediated through mast cell degranulation and activation of the Gq/11-protein coupled neurosteroid receptor, PLC and intracellular Ca2+ mobilization.
|
SUPPLEMENTARY DATA |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
Supplementary data are available online at www.toxsci.oxfordjournals.org.
|
ACKNOWLEDGMENTS |
|---|
We thank Prof. Motomasa Kobayashi for providing xestospongin C. Parts of this study were supported by Health Sciences Research Grants for Research on Environmental Health from the Ministry of Health, Labor and Welfare of Japan, Grants for the Nagasaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST and Grants-in-Aid from the Ministry of Education, Science, Culture and Sports of Japan. This study was also supported by grants from the CREST Project of JST for Endocrine Disruption on Action of Brain Neurosteroids.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSAtrazine-Reversible PROG-BSA...DISCUSSIONSUPPLEMENTARY DATAREFERENCES |
|---|
Aussel, C., Marhaba, R., Pelassy, C., and Breittmayer, J. P. (1996). Submicromolar La3+ concentrations block the calcium release-activated channel, and impair CD69 and CD25 expression in CD3- or thapsigargin-activated Jurkat cells. Biochem. J. 313, 909–913.[Medline]
Baulieu, E. E. (1989). Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245, 1351–1357.
Benten, W. P., Lieberherr, M., Giese, G., Wrehlke, C., Stamm, O., Sekeris, C. E., Mossmann, H., and Wunderlich, F. (1999). Functional testosterone receptors in plasma membranes of T cells. Faseb J. 13, 123–133.
Chen, C. W. (2001). Assessment of endocrine disruptors: Approaches, issues, and uncertainties. Folia Histochem. Cytobiol. 39(Suppl. 2), 20–23.
Demo, S. D., Masuda, E., Rossi, A. B., Throndset, B. T., Gerard, A. L., Chan, E. H., Armstrong, R. J., Fox, B. P., Lorens, J. B., Payan, D. G., et al. (1999). Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay. Cytometry 36, 340–348.[CrossRef][Web of Science][Medline]
Dohi, T., Kitayama, S., Morioka, N., Kumagai, K., Mitsuhata, C., Morita, K., Kozai, K., Lin, Z., and Uhl, G. R. (2004). Regulation of dopamine and MPP+ transport by catecholamine transporters. Nihon Shinkei Seishin Yakurigaku Zasshi 24, 43–47.[Medline]
Fish, S. C., Donaldson, D. D., Goldman, S. J., Williams, C. M., and Kasaian, M. T. (2005). IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J. Immunol. 174, 7716–7724.
Gafni, J., Munsch, J. A., Lam, T. H., Catlin, M. C., Costa, L. G., Molinski, T. F., and Pessah, I. N. (1997). Xestospongins: Potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 19, 723–733.[CrossRef][Web of Science][Medline]
Hayes, T., Haston, K., Tsui, M., Hoang, A., Haeffele, C., and Vonk, A. (2002). Herbicides: Feminization of male frogs in the wild. Nature 419, 895–896.[CrossRef][Medline]
Hong-Geller, E., and Cerione, R. A. (2000). Cdc42 and Rac stimulate exocytosis of secretory granules by activating the IP3/calcium pathway in RBL-2H3 mast cells. J. Cell. Biol. 148, 481–494.
Howell, A., Osborne, C. K., Morris, C., and Wakeling, A. E. (2000). ICI 182,780 (Faslodex): Development of a novel, "pure" antiestrogen. Cancer 89, 817–825.[CrossRef][Web of Science][Medline]
Inoue, M., Tokuyama, S., Nakayamada, H., and Ueda, H. (1998). In vivo signal transduction of tetrodotoxin-sensitive nociceptive responses by substance P given into the planta of the mouse hind limb. Cell. Mol. Neurobiol. 18, 555–561.[CrossRef][Web of Science][Medline]
Kobayashi, M., Kawazoe, K., and Kitagawa, I. (1989). Araguspongines B, C, D, E, F, G, H, and J, new vasodilative bis-1-oxaquinolizidine alkaloids from an okinawan marine sponge, Xestospongia sp. Chem. Pharm. Bull. (Tokyo) 37, 1676–1678.[Medline]
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., and Paul, S. M. (1986). Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232, 1004–1007.
McLachlan, J. A. (2001). Environmental signaling: What embryos and evolution teach us about endocrine disrupting chemicals. Endocr. Rev. 22, 319–341.
Mizota, K., Yoshida, A., Uchida, H., Fujita, R., and Ueda, H. (2005). Novel type of Gq/11 protein-coupled neurosteroid receptor sensitive to endocrine disrupting chemicals in mast cell line (RBL-2H3). Br. J. Pharmacol. 145, 545–550.[CrossRef][Web of Science][Medline]
Mori, S., Saino, T., and Satoh, Y. (2000). Effect of low temperatures on compound 48/80-induced intracellular Ca2+ changes and exocytosis of rat peritoneal mast cells. Arch. Histol. Cytol. 63, 261–270.[CrossRef][Web of Science][Medline]
Nadal, A., Ropero, A. B., Fuentes, E., and Soria, B. (2001). The plasma membrane estrogen receptor: Nuclear or unclear? Trends Pharmacol. Sci. 22, 597–599.[CrossRef][Medline]
Nadal, A., Ropero, A. B., Laribi, O., Maillet, M., Fuentes, E., and Soria, B. (2000). Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc. Natl. Acad. Sci. U.S.A. 97, 11603–11608.
Rupprecht, R., and Holsboer, F. (1999). Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22, 410–416.[CrossRef][Web of Science][Medline]
Senyshyn, J., Baumgartner, R. A., and Beaven, M. A. (1998). Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway. J. Immunol. 160, 5136–5144.
Smith, A. J., Surviladze, Z., Gaudet, E. A., Backer, J. M., Mitchell, C. A., and Wilson, B. S. (2001). p110beta and p110delta phosphatidylinositol 3-kinases up-regulate Fc(epsilon)RI-activated Ca2+ influx by enhancing inositol 1,4,5-trisphosphate production. J. Biol. Chem. 276, 17213–17220.
Uchida, H., Mizuno, K., Yoshida, A., and Ueda, H. (2003). Neurosteroid-induced hyperalgesia through a histamine release is inhibited by progesterone and p,p'-DDE, an endocrine disrupting chemical. Neurochem. Int. 42, 401–7.[CrossRef][Web of Science][Medline]
Ueda, H., and Inoue, M. (2000). In vivo signal transduction of nociceptive response by kyotorphin (tyrosine-arginine) through Galphai- and inositol trisphosphate-mediated Ca2+ influx. Mol. Pharmacol. 57, 108–115.
Ueda, H., Inoue, M., Yoshida, A., Mizuno, K., Yamamoto, H., Maruo, J., Matsuno, K., and Mita, S. (2001a). Metabotropic neurosteroid/sigma-receptor involved in stimulation of nociceptor endings of mice. J. Pharmacol. Exp. Ther. 298, 703–710.
Ueda, H., Yoshida, A., Tokuyama, S., Mizuno, K., Maruo, J., Matsuno, K., and Mita, S. (2001b). Neurosteroids stimulate G protein-coupled sigma receptors in mouse brain synaptic membrane. Neurosci. Res. 41, 33–40.[CrossRef][Web of Science][Medline]
US Environmental Protection Agency. (2003). US EPA Publication Available at: http://www.epa.gov/oppsrrd1/reregistration/atrazine/ Accessed November 7, 2004.
Windmiller, D. A., and Backer, J. M. (2003). Distinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus FcepsilonRI receptors. J. Biol. Chem. 278, 11874–11878.
Wu, F. S., Gibbs, T. T., and Farb, D. H. (1991). Pregnenolone sulfate: A positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol. Pharmacol. 40, 333–336.[Abstract]
Zimmermann, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16, 109–110.[CrossRef][Web of Science][Medline]
Zussman, A., and Sagi-Eisenberg, R. (2000). Stimulation of Ca2+-dependent exocytosis and release of arachidonic acid in cultured mast cells (RBL-2H3) by quercetin. Int. J. Immunopharmacol. 22, 747–754.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Ji, S. Zhu, Z. Liu, V. R. Dharnidharka, B. Hocking, N. Guan, J. Ding, and C. B. Langman Melamine-Contaminated Powdered Formula and Urolithiasis N. Engl. J. Med., June 18, 2009; 360(25): 2675 - 2678. [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Hotchkiss, C. V. Rider, C. R. Blystone, V. S. Wilson, P. C. Hartig, G. T. Ankley, P. M. Foster, C. L. Gray, and L. E. Gray Fifteen Years after "Wingspread"--Environmental Endocrine Disrupters and Human and Wildlife Health: Where We are Today and Where We Need to Go Toxicol. Sci., October 1, 2008; 105(2): 235 - 259. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||